wellrank.ai

My insurance denied Wegovy. Are compounded GLP-1s my best option?

ClaudediscoveryCollected Jul 4, 2026, 12:49 UTC

Verbatim response from Claude

This is a really common situation right now. Here are some honest options to consider:

Compounded GLP-1s (Semaglutide)

Pros:

  • Significantly cheaper (~$200-400/month vs $1,300+)
  • Accessible without insurance approval

Cons:

  • FDA has raised safety concerns about compounded versions
  • Quality varies by pharmacy
  • Now in a legal gray area - the FDA declared semaglutide off the shortage list, meaning many compounders must stop

Specific Options Worth Considering

Telehealth platforms with compounded GLP-1s:

  • Hims/Hers - transparent, established company
  • Ro - reputable platform with medical oversight
  • Henry - straightforward pricing

Better long-term approaches:

  • Appeal your insurance denial - ask your doctor for a peer-to-peer review; approval rates improve significantly
  • Novo Nordisk's savings program - can reduce cost to ~$650/month with commercial insurance
  • Try Zepbound (tirzepatide) - sometimes easier to get covered than Wegovy
  • Ozempic - same drug (semaglutide), sometimes covered for diabetes diagnosis

My Honest Recommendation

Appeal first before going the compound route, given the regulatory uncertainty. Your doctor advocating directly to your insurer is often the most effective step.

Would you like help thinking through the appeal process?

Brands mentioned in this answer

Is this answer wrong about your brand?

AI engines repeat outdated pricing, wrong ingredients, and misread positioning every day. Tell us what this answer gets wrong and we will include a correction review in your free AI Visibility Audit.

This answer is reproduced verbatim from the engine's API at collection time and may contain errors or outdated claims. It is presented as evidence of what AI engines tell buyers, not as medical or purchasing advice.

Is your brand missing from this answer?

Get your AI Visibility Audit: every buyer intent question you are losing, who wins them, and the sources that decide the answer.